Prostate Cancer Biochemical Recurrence Risk Stratification Falls Short
As currently defined, biochemical recurrence after surgery or radiation is not a reliable predictor of the risk of death from prostate cancer, investigators say.
As currently defined, biochemical recurrence after surgery or radiation is not a reliable predictor of the risk of death from prostate cancer, investigators say.
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Local testosterone delivery to the prostate bed might be a better marker of post-prostatectomy outcomes than serum testosterone in some men.
Biochemical recurrence endpoints did not reliably predict overall survival in prostate cancer trials.
Patients with prostate cancer who have visceral metastases limited to the lung have the best prognosis, a study suggests.
A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators reported.
MRI screening can catch prostate cancers missed by PSA testing, researchers found.
Some cancer centers have lifted mask mandates that were intended to protect patients from COVID-19, despite patient concerns.
Study findings support attempting nerve-sparing surgery in patients with confirmed high-risk prostate cancer.